Summary
Global Markets Direct’s, ‘Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2016’, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
- The report reviews pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anaplastic Large Cell Lymphoma (ALCL) therapeutics and enlists all their major and minor projects
- The report assesses Anaplastic Large Cell Lymphoma (ALCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anaplastic Large Cell Lymphoma (ALCL)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ariad Pharmaceuticals, Inc.
AstraZeneca Plc
Bayer AG
Celon Pharma Sp. z o.o.
Pfizer Inc.
Sareum Holdings Plc
Seattle Genetics, Inc.
Teva Pharmaceutical Industries Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anaplastic Large Cell Lymphoma (ALCL) Overview 7
Therapeutics Development 8
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview 8
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies 9
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies 13
Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development 14
Ariad Pharmaceuticals, Inc. 14
AstraZeneca Plc 15
Bayer AG 16
Celon Pharma Sp. z o.o. 17
Pfizer Inc. 18
Sareum Holdings Plc 19
Seattle Genetics, Inc. 20
Teva Pharmaceutical Industries Ltd. 21
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AdIL-24 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
AZD-3463 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
brentuximab vedotin - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
brigatinib - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
CEP-37440 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
copanlisib hydrochloride - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
crizotinib - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
SAR-3 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
SAR-4 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
SH-7129 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects 81
Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products 82
Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones 83
Featured News & Press Releases 83
Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma 83
Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma 84
Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting 85
Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 87
Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 89
Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 91
Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress 92
Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan 93
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 93
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 94
Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma 96
Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma 98
May 14, 2013: Seattle Genetics Announces Adcetris Supplemental BLA Accepted For Filing By FDA 99
Mar 22, 2013: Takeda Submits New Drug Application For Brentuximab Vedotin In Japan 100
Mar 18, 2013: Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With Adcetris In Relapsed Hodgkin Lymphoma And Systemic ALCL 101
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 103
Disclaimer 104
List of Tables
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016 14
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca Plc, H2 2016 15
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H2 2016 16
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H2 2016 17
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H2 2016 18
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings Plc, H2 2016 19
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H2 2016 20
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H2 2016 81
Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H2 2016 82
List of Figures
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Top 10 Targets, H2 2016 23
Number of Products by Stage and Top 10 Targets, H2 2016 23
Number of Products by Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 27
Number of Products by Stage and Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 29
